NextCure NXTC 深 沪
等待开盘 09-24 09:30:00 美东时间
5.7338
+0.174
+3.13%
华盛通- 最 高5.79
- 今 开5.41
- 成交量 2176股
- 最 低 5.41
- 昨 收 5.56
- 总市值 1534.42万
- 52周最高 19.20
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 2.688
- 委 比 -99.90%
- 总股本 267.61万
- 历史最高 1308.00
- 量 比 0.37
- 振 幅 6.83%
- 历史最低 2.688
- 每 手 1
- 风险率 4.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NextCure, Inc. will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 4:00 pm ET in New York City. A live audio webcast will be available on the company’s website, www.nextcure.com, with a replay archived for 30 days. NextCure focuses on developing innovative cancer therapies, including antibody-drug conjugates, targeting patients who do not respond to current treatments. For m...
09-04 11:00
先声药业2025年中报：创新药收入增长26%，经调整净利润增长21%
8月21日，先声药业（02096.HK）发布2025年中期业绩报告。2025年上半年，先声药业集团总营业收入同比增长15.1%至35.85亿元，经调整净利润6...
08-22 14:10
先声药业上半年营收35.85亿元，创新药收入同比增长26%
（来源：真灼财经） 先声药业(02096.HK)公布截至2025年6月30日止六个月的中期业绩。期内公司实现收入35.85亿元人民币，同比增长15.1%；创新...
08-22 13:10
中泰证券：创新药企分化加剧 重点推荐先声药业等创新药标杆企业
近期以来，医药板块行情呈现多元化趋势：从创新药单主线驱动，逐步延伸至业绩反转、脑机接口及AI制药等新兴领域，同时创新药内部结构性分化加剧，市场风格呈现高低切...
08-12 10:02
NextCure GAAP EPS of -$11.29
NextCure press release (NASDAQ:NXTC): Q2 GAAP EPS of -$11.29. Cash, cash equivalents, and marketable securities as of June 30, 2025 were $35.3 million as compared to $68.6 million as of December 31, 2...
08-09 02:04
NextCure Q2 EPS $(11.29) Misses $(0.39) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(11.29) per share which missed the analyst consensus estimate of $(0.39) by 2832.47 percent. This is a 70.8 percent decrease over losses of $(6.61) per share from the
08-08 04:58
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
NextCure, Inc., a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, announced strategic progress in their ADC programs SIM0505 (targeting CDH6) and LNCB74 (targeting B7-H4). NextCure plans to dose the first SIM0505 patient in the U.S. this quarter and provide updates on both programs by Q4 2025, along with proof of concept data in H1 2026. Financially, the company reported a net loss of $26.8 million for Q2 20...
08-07 20:05
NextCure Presented New Preclinical Data In A Well-Established Model Of Osteogenesis Imperfecta Demonstrating That Treatment With NC605 Achieved Improved Bone Microarchitecture And Reduced Fracture Incidence Compared To Anti-Sclerostin Treatment
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies
07-25 04:11
